Assessment of Clinical Questionnaires for Predicting Obstructive Sleep Apnea in Patients with Non-Valvular Atrial Fibrillation.

IF 3.4 Q2 RESPIRATORY SYSTEM

Pulmonary Therapy Pub Date : 2026-06-01 Epub Date: 2026-03-13 DOI:10.1007/s41030-026-00356-z

Thu Nguyen Ngoc Phuong, Thanh V Kim, Duong Hiep Ho, Thuong Thanh Phuong, Nguyen Thi Le Trang, Tran Thanh Tuyen, Bui Dan Que, Doan Thi Hoa, Ngo Thi Thanh Thao, Sy Duong-Quy

{"title":"Assessment of Clinical Questionnaires for Predicting Obstructive Sleep Apnea in Patients with Non-Valvular Atrial Fibrillation.","authors":"Thu Nguyen Ngoc Phuong, Thanh V Kim, Duong Hiep Ho, Thuong Thanh Phuong, Nguyen Thi Le Trang, Tran Thanh Tuyen, Bui Dan Que, Doan Thi Hoa, Ngo Thi Thanh Thao, Sy Duong-Quy","doi":"10.1007/s41030-026-00356-z","DOIUrl":null,"url":null,"abstract":"Introduction: Obstructive sleep apnea (OSA) is common but frequently underdiagnosed in patients with atrial fibrillation (AF), particularly in low- and middle-income countries, where access to polysomnography is limited. This study evaluated the diagnostic accuracy of the STOP-BANG, Berlin, and Epworth Sleepiness Scale (ESS) questionnaires for OSA screening in Vietnamese patients with non-valvular AF.Methods: This cross-sectional diagnostic accuracy study was conducted in a tertiary inpatient cardiology department in Ho Chi Minh City, Vietnam. Consecutive adults with chronic non-valvular AF completed the STOP-BANG, Berlin, and ESS questionnaires, followed by overnight unattended type III polysomnography (ApneaLink™, ResMed). OSA was defined as an apnea-hypopnea index ≥ 5 events/hour according to International Classification of Sleep Disorders (ICSD)-3 criteria. Diagnostic performance was assessed using sensitivity, specificity, area under the receiver operating characteristic curve (AUC), predictive values, and likelihood ratios.Results: Among 126 participants (median age 61 years; 45.2% male vs. 54.8% female), OSA prevalence was 74.6%. STOP-BANG showed the highest diagnostic accuracy (AUC 0.903, 95% confidence interval [95% CI] 0.852-0.954), with sensitivity of 81.9% and specificity of 96.9%. The Berlin questionnaire demonstrated moderate performance (AUC 0.824, 95% CI 0.735-0.914; sensitivity 89.4%; specificity 59.4%). ESS performed poorly in this population (AUC 0.499, 95% CI 0.386-0.613; sensitivity 6.4%).Conclusions: STOP-BANG demonstrated superior diagnostic accuracy and practicality for OSA screening in patients with non-valvular AF, supporting its use to guide referrals for confirmatory sleep testing in resource-limited settings.","PeriodicalId":20919,"journal":{"name":"Pulmonary Therapy","volume":" ","pages":"561-572"},"PeriodicalIF":3.4000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13287176/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s41030-026-00356-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Obstructive sleep apnea (OSA) is common but frequently underdiagnosed in patients with atrial fibrillation (AF), particularly in low- and middle-income countries, where access to polysomnography is limited. This study evaluated the diagnostic accuracy of the STOP-BANG, Berlin, and Epworth Sleepiness Scale (ESS) questionnaires for OSA screening in Vietnamese patients with non-valvular AF.

Methods: This cross-sectional diagnostic accuracy study was conducted in a tertiary inpatient cardiology department in Ho Chi Minh City, Vietnam. Consecutive adults with chronic non-valvular AF completed the STOP-BANG, Berlin, and ESS questionnaires, followed by overnight unattended type III polysomnography (ApneaLink™, ResMed). OSA was defined as an apnea-hypopnea index ≥ 5 events/hour according to International Classification of Sleep Disorders (ICSD)-3 criteria. Diagnostic performance was assessed using sensitivity, specificity, area under the receiver operating characteristic curve (AUC), predictive values, and likelihood ratios.

Results: Among 126 participants (median age 61 years; 45.2% male vs. 54.8% female), OSA prevalence was 74.6%. STOP-BANG showed the highest diagnostic accuracy (AUC 0.903, 95% confidence interval [95% CI] 0.852-0.954), with sensitivity of 81.9% and specificity of 96.9%. The Berlin questionnaire demonstrated moderate performance (AUC 0.824, 95% CI 0.735-0.914; sensitivity 89.4%; specificity 59.4%). ESS performed poorly in this population (AUC 0.499, 95% CI 0.386-0.613; sensitivity 6.4%).

Conclusions: STOP-BANG demonstrated superior diagnostic accuracy and practicality for OSA screening in patients with non-valvular AF, supporting its use to guide referrals for confirmatory sleep testing in resource-limited settings.

查看原文本刊更多论文

预测非瓣膜性心房颤动患者阻塞性睡眠呼吸暂停的临床问卷评估。

导读：阻塞性睡眠呼吸暂停（OSA）在房颤（AF）患者中很常见，但经常被误诊，特别是在多导睡眠图检测有限的中低收入国家。本研究评估了STOP-BANG、Berlin和Epworth睡意量表（ESS）问卷对越南非瓣膜性心房炎患者OSA筛查的诊断准确性。方法：本横断诊断准确性研究在越南胡志明市的一家三级住院心内科进行。患有慢性非瓣膜性房事的连续成年人完成了STOP-BANG、Berlin和ESS问卷调查，随后进行了夜间无人监护的III型多导睡眠描图（ApneaLink™，ResMed）。根据国际睡眠障碍分类(ICSD)-3标准，将OSA定义为呼吸暂停-低通气指数≥5次/小时。采用敏感性、特异性、受试者工作特征曲线下面积（AUC）、预测值和似然比评估诊断效果。结果：126名参与者（中位年龄61岁，45.2%为男性，54.8%为女性），OSA患病率为74.6%。STOP-BANG的诊断准确率最高（AUC 0.903, 95%可信区间[95% CI] 0.852 ~ 0.954），敏感性为81.9%，特异性为96.9%。柏林问卷表现出中等的表现（AUC 0.824, 95% CI 0.735-0.914；敏感性89.4%；特异性59.4%）。ESS在该人群中表现不佳（AUC 0.499, 95% CI 0.386-0.613；敏感性6.4%）。结论：STOP-BANG在非瓣膜性房颤患者的OSA筛查中表现出卓越的诊断准确性和实用性，支持其在资源有限的情况下指导转诊进行确证性睡眠测试。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pulmonary Therapy Medicine-Pulmonary and Respiratory Medicine

CiteScore

5.20

自引率

3.30%

发文量

审稿时长

6 weeks

期刊介绍： Aims and Scope Pulmonary Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from pre-clinical, clinical (all phases), observational, real-world, and health outcomes research around the use of pulmonary therapies, devices, and surgical techniques. Areas of focus include, but are not limited to: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other respiratory allergies; influenza, pneumococcal infection, respiratory syncytial virus and other respiratory infections; and inhalers and other device therapies. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. Pulmonary Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. Rapid Publication The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of pulmonary therapies. Open Access All articles published by Pulmonary Therapy are open access. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. Digital Features and Plain Language Summaries Pulmonary Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/ Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €4500/ $5100/ £3650. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis. Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials, and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in one of our journals. Once the manuscript is published, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website. Please follow the link for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Copyright Pulmonary Therapy''s content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0. Contact For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.